Therapeutic Effect of Tanshinone IIA on Liver Fibrosis and the Possible Mechanism: A Preclinical Meta-Analysis
Autor: | Yangyang Teng, Qingji Ying, Zhanxiong Xue, Zhenzhai Cai, Jing Zhang |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
Drug
Oncology 0303 health sciences medicine.medical_specialty business.industry Mechanism (biology) media_common.quotation_subject Therapeutic effect Publication bias Review Article lcsh:Other systems of medicine lcsh:RZ201-999 03 medical and health sciences 0302 clinical medicine Clinical research Complementary and alternative medicine Internal medicine Meta-analysis Medicine 030211 gastroenterology & hepatology Animal studies Liver function business 030304 developmental biology media_common |
Zdroj: | Evidence-Based Complementary and Alternative Medicine, Vol 2019 (2019) Evidence-based Complementary and Alternative Medicine : eCAM |
ISSN: | 1741-4288 |
Popis: | Background. Liver fibrosis is a serious human health problem, and there is a need for specific antifibrosis drugs in the clinic. Tanshinone IIA has recently been reported to have a role in the treatment of liver fibrosis. However, the evidence supporting its antifibrotic effect is not sufficient, and the underlying mechanism is not clear. We thus performed this meta-analysis of animal research to assess the therapeutic effect of tanshinone IIA on liver fibrosis and analyzed the possible associated mechanism to provide a reference for further clinical drug preparation and clinical research. Methods. We collect related articles from the databases PubMed, Web of Science, Embase, Wanfang, VIP, and CNKI. The quality of the included studies was evaluated according to the SYRCLE risk of bias tool for animal studies. Data were analyzed using RavMan 5.3 and Stata 12.0 software. Results. A total of 404 articles were retrieved from the databases. After screening, 11 articles were included in the analysis. The included studies’ methodological quality was generally low, and an obvious publication bias was found. The results showed that tanshinone IIA significantly improved liver function in experimental animals and reduced the level of liver fibrosis by reducing inflammation and inhibiting immunity, antiapoptotic processes, and HSC activation. Conclusion. Tanshinone IIA can effectively improve liver fibrosis and liver function in animal models and is worthy of future higher quality animal studies and clinical drug trials. |
Databáze: | OpenAIRE |
Externí odkaz: |